Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

Also, Amgen’s weight loss drug had little chance to gain market share because of Lilly’s and Novo’s dominance. Data shows ...

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

1 The research firm reached its conclusion based on a recent study that suggests that Zepbound may be more effective at promoting weight loss than Wegovy. The findings also took into consideration ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Zepbound is a prescription injectable medication that’s used for weight loss. You or a caregiver can administer it as a subcutaneous injection into your stomach or thigh. A caregiver can also ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

which will determine whether compounding pharmacies and facilities can keep selling cheaper versions of the company's weight-loss drug Zepbound and diabetes medicine Mounjaro, which have the same ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.